Settlement supplies folks with broader get right of entry to to a protein-based non-mRNA adjuvanted COVID-19 vaccine via mixed industrial power, from 2025 onwardsProvides Novavax with money and an fairness funding totalling roughly $1.2 billion (prematurely cost of $500 million and as much as $700 million in more building, regulatory and release milestones), plus tiered royaltiesNovavax is entitled to further release and gross sales milestone alternatives of as much as $200 million, plus mid-single digit royalties, for each and every further Sanofi vaccine product advanced beneath a non-exclusive license with Novavax’s Matrix-M™ adjuvant technologyAccelerates possible for building of a singular COVID-19-Influenza mixture product in line with approved vaccines with demonstrated efficacy and tolerability, doubtlessly providing folks enhanced comfort and protectionGAITHERSBURG, Md., Would possibly 10, 2024 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a world corporate advancing protein-based vaccines with its Matrix-M™ adjuvant, has entered right into a co-exclusive licensing settlement with Sanofi (Nasdaq: SNY).The phrases of the settlement come with: a co-exclusive license to co-commercialize Novavax’s present stand-alone adjuvanted COVID-19 vaccine international (with the exception of in international locations with present Advance Acquire Agreements and in India, Japan and South Korea the place Novavax has present partnership agreements); a sole license to Novavax’s adjuvanted COVID-19 vaccine to be used together with Sanofi’s flu vaccines whilst Novavax keeps the correct to and is creating its personal COVID-19-Influenza Mixture vaccine candidate; a non-exclusive license to make use of Novavax’s adjuvanted COVID-19 vaccine to be used together with non-flu vaccines; and a non-exclusive license to make use of the Matrix-M adjuvant in vaccine merchandise. As well as, Sanofi will take a minority (<5%) fairness funding in Novavax.”With flu and COVID-19 health center admission charges now carefully mirroring each and every different, we’ve a possibility to expand non-mRNA flu-COVID-19 mixture vaccines, providing sufferers each enhanced comfort and coverage towards two severe breathing viruses,” stated Jean-Francois Toussaint, International Head of Vaccines R&D, Sanofi. “We are enthusiastic about the chance of mixing Novavax’s adjuvanted COVID-19 vaccine that has proven top efficacy and favorable tolerability, with our wealthy portfolio of differentiated flu vaccines that experience demonstrated awesome coverage towards flu and its severe headaches. Advanced tolerability and thermostability, with out compromise on efficacy, are what regulators, recommending our bodies and sufferers will call for.””This collaboration is vital for Novavax and for world public well being. Our new partnership combines Novavax’s proprietary recombinant protein and nanoparticle applied sciences, Matrix™ adjuvant and R&D experience with Sanofi’s world-class management in launching and commercializing cutting edge vaccines. In combination, we will increase get right of entry to to each our COVID-19 vaccine and our adjuvant to make sure extra folks can get pleasure from the security vaccines may give,” stated John C. Jacobs, President and Leader Government Officer, Novavax. “Novavax is now in a more potent place to refocus our efforts on leveraging our era platform and novel adjuvant in R&D and pipeline enlargement to assist advance our undertaking of creating life-saving vaccines to battle infectious sicknesses.”Underneath the phrases of the licensing settlement:Novavax will obtain an prematurely cost of $500 million and as much as $700 million in building, regulatory and release milestones, as much as $1.2 billion in overall.Beginning in 2025, Sanofi will e book gross sales of Novavax’s adjuvanted COVID-19 vaccine and can make stronger sure R&D, regulatory and industrial bills.Novavax will obtain tiered double-digit proportion royalty bills on gross sales via Sanofi of COVID-19 vaccines and COVID-19-Influenza Mixture vaccines.Sanofi might be only chargeable for building and commercialization of any novel flu-COVID-19 mixture vaccine containing a Sanofi flu vaccine.Outdoor of the collaboration, each and every birthday celebration would possibly expand and commercialize their very own COVID-19-Influenza mixture vaccines and adjuvanted merchandise at their very own price.Novavax is entitled to further release and gross sales milestone alternatives of as much as $200 million, plus mid-single digit royalties for each and every further Sanofi vaccine product advanced beneath a non-exclusive license with Novavax’s Matrix-M adjuvant era.As well as, Sanofi will take a minority (<5%) fairness funding in Novavax.PJT Companions is performing because the unique monetary consultant to Novavax. Ropes & Grey LLP is serving as felony consultant.About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes progressed well being via finding, creating and commercializing cutting edge vaccines to assist give protection to towards severe infectious sicknesses. Novavax, a world corporate founded in Gaithersburg, Md., U.S., provides a differentiated vaccine platform that mixes a recombinant protein manner, cutting edge nanoparticle era and Novavax’s patented Matrix-M adjuvant to toughen the immune reaction. The Corporate’s portfolio comprises its COVID-19 vaccine and its pipeline comprises its COVID-19-Influenza Mixture and stand-alone influenza vaccine applicants. As well as, Novavax’s adjuvant is integrated within the College of Oxford and Serum Institute of India’s R21/Matrix-M™ malaria vaccine. Please consult with novavax.com and LinkedIn for more info.About Sanofi
We’re an cutting edge world healthcare corporate, pushed via one objective: we chase the miracles of science to make stronger other folks’s lives. Our staff, the world over, is devoted to remodeling the apply of medication via running to show the not possible into the imaginable. We offer doubtlessly life-changing remedy choices and life-saving vaccine coverage to tens of millions of other folks globally, whilst hanging sustainability and social duty on the heart of our ambitions.Ahead-Taking a look Statements
Statements herein in relation to enhanced get right of entry to to a protein-based non-mRNA adjuvanted COVID-19 from 2025 onwards, building of COVID-19 mixture vaccines (together with COVID-19-Influenza mixture vaccines), launching a segment 3 trial for Novavax’s COVID-19-Influenza Mixture vaccine candidate in the second one part of 2024, long term vaccines made with Novavax’s proprietary Matrix-MTM adjuvant, possible royalties and milestones, the way forward for Novavax and its undertaking are forward-looking statements. Novavax cautions that those forward-looking statements are matter to a large number of dangers and uncertainties that might reason exact effects to fluctuate materially from the ones expressed or implied via such statements. Those dangers and uncertainties come with, with out limitation, Novavax’s and Sanofi’s talent to effectively enforce its partnership, together with the power to transition key processes and impact era transfers; Novavax’s talent to effectively and well timed manufacture, distribute, or marketplace its up to date COVID-19 vaccine together with as a unmarried dose vial or pre-filled syringe product presentation for the 2024-2025 vaccination season; demanding situations pleasing, on my own or along side companions, more than a few protection, efficacy, and product characterization necessities, together with the ones associated with procedure qualification, assay validation and balance trying out, important to meet appropriate regulatory government; demanding situations or delays in engaging in medical trials; demanding situations or delays in acquiring regulatory authorization for its product applicants, together with its up to date COVID-19 vaccine in time for the 2024-2025 vaccination season or for long term COVID-19 variant pressure adjustments, its COVID-19-Influenza Mixture vaccine candidate and its stand-alone influenza vaccine candidate; production, distribution or export delays or demanding situations; Novavax’s considerable dependence on Serum Institute of India Pvt. Ltd. and Serum Lifestyles Sciences Restricted for co-formulation and filling and PCI Pharma Products and services for completing Novavax’s COVID-19 vaccine and the affect of any delays or disruptions of their operations at the supply of purchaser orders; issue acquiring scarce uncooked fabrics and provides; useful resource constraints, together with human capital and production capability, constraints on Novavax’s talent to pursue deliberate regulatory pathways, on my own or with companions, in more than one jurisdictions concurrently, resulting in staggering of regulatory filings, and possible regulatory movements; demanding situations in imposing its world restructuring and price aid plan; Novavax’s talent to well timed ship doses; demanding situations in acquiring industrial adoption and marketplace acceptance of its up to date COVID-19 vaccine or any COVID-19 variant pressure containing formulas; demanding situations assembly contractual necessities beneath agreements with more than one industrial, governmental, and different entities, together with necessities to ship doses that can require Novavax to refund parts of prematurely and different bills prior to now won or lead to decreased long term bills pursuant to such agreements; demanding situations associated with the seasonality of vaccinations towards COVID-19; and the ones different chance elements known within the “Chance Components” and “Control’s Dialogue and Research of Monetary Situation and Result of Operations” sections of Novavax’s Annual File on Shape 10-Ok for the yr ended December 31, 2023 as filed with the Securities and Alternate Fee (SEC). We warning buyers to not position substantial reliance on forward-looking statements contained on this press free up. You might be inspired to learn our filings with the SEC, to be had at www.sec.gov and www.novavax.com, for a dialogue of those and different dangers and uncertainties. The forward-looking statements on this press free up discuss simplest as of the date of this record, and we adopt no legal responsibility to replace or revise any of the statements. Our industry is matter to considerable dangers and uncertainties, together with the ones referenced above. Buyers, possible buyers, and others will have to give cautious attention to those dangers and uncertainties.Contacts:
Buyers
Erika Schultz
240-268-2022
[email protected]Media
Giovanna Chandler
240-720-7804
[email protected]
SOURCE NOVAVAX, INC
